论文部分内容阅读
目的:探讨小剂量奥氮平在实体瘤化疗止吐中的应用价值。方法:按照动态随机对照原则,将60例2011-08-02-2012-07-31在河北医科大学第四医院肿瘤内科住院的实体瘤化疗的患者动态随机分为干预组和对照组,每组30例。干预组在常规化疗同时,给予常规止吐药物及口服小剂量奥氮平(奥氮平2.5mg,早、晚各1次口服;或5mg,每晚口服1次),对照组仅给予常规止吐药物治疗。观察恶心呕吐的发生率和其他不良反应发生率。结果:干预组完全缓解22例(73.3%),部分缓解5例(16.7%),轻度缓解2例(6.6%),无效1例(3.3%),有效率为90.0%;对照组,完全缓解11例(36.7%),部分缓解14例(46.7%),轻度缓解4例(13.3%),无效1例(3.3%),有效率为(83.3%)。两组疗效差异有统计学意义,χ2=8.596,P=0.035。患者的化疗依从性干预组明显优于对照组,便秘等其他不良反应两组差异无统计学意义,P>0.05。结论:常规止吐治疗联合小剂量奥氮平在实体瘤化疗中,可以明显减轻患者化疗相关恶心呕吐的发生率,不良反应耐受性好,提高患者的化疗依从性。
Objective: To investigate the value of low-dose olanzapine in the treatment of solid tumor chemotherapy and antiemetic. Methods: According to the principle of dynamic randomized control, 60 patients with solid tumor chemotherapy in hospitalized in the Department of Oncology, the Fourth Hospital of Hebei Medical University from 2011-08-02 to July 31, 2011 were randomly divided into intervention group and control group, with each group 30 cases. In the intervention group, conventional antiemetic drugs and oral low-dose olanzapine (olanzapine 2.5mg, once every morning and evening orally; or 5mg once daily orally) were given routinely. The control group was only given routine Spit drug treatment. To observe the incidence of nausea and vomiting and other adverse reactions. Results: In the intervention group, complete remission was achieved in 22 cases (73.3%), partial remission in 5 cases (16.7%), mild remission in 2 cases (6.6%) and ineffectiveness in 1 case (3.3%), with an effective rate of 90.0% Eleven patients (36.7%) were relieved, 14 patients (46.7%) partially relieved, 4 patients (13.3%) mildly relieved, and 1 (3.3%) ineffective. The effective rate was 83.3%. The difference between the two groups was statistically significant, χ2 = 8.596, P = 0.035. Patients in the chemotherapy compliance group was significantly better than the control group, constipation and other adverse reactions in the two groups showed no significant difference (P> 0.05). Conclusion: Conventional antiemetic treatment combined with low-dose olanzapine can obviously reduce the incidence of chemotherapy-related nausea and vomiting in patients with solid tumor chemotherapy. The adverse reactions are well tolerated and the chemotherapy compliance is improved.